2019 - Member of the National Academy of Medicine (NAM)
Immunology, Immunotherapy, Antigen, Chimeric antigen receptor and Cancer research are his primary areas of study. His Immunology research is multidisciplinary, relying on both Cytotoxic T cell and Internal medicine. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology and Surgery.
The Immunotherapy study which covers Chronic lymphocytic leukemia that intersects with Targeted therapy. The concepts of his Antigen study are interwoven with issues in Adoptive cell transfer and T-cell receptor. His work is dedicated to discovering how Chimeric antigen receptor, Receptor are connected with Mutation and other disciplines.
His primary areas of study are Internal medicine, Immunology, Chimeric antigen receptor, Cancer research and Oncology. His Internal medicine research includes elements of Gastroenterology and Surgery. His study in Chimeric antigen receptor is interdisciplinary in nature, drawing from both Antigen, CD19 and Cell therapy.
His studies deal with areas such as Sirolimus, Lymphoblastic Leukemia, Apoptosis, PI3K/AKT/mTOR pathway and Receptor as well as Cancer research. Stephan A. Grupp has included themes like Clinical trial, Young adult, Minimal residual disease, Stem cell and Neuroblastoma in his Oncology study. Stephan A. Grupp combines subjects such as Tocilizumab, Chimeric Antigen Receptor T-Cell Therapy and Refractory with his study of Cytokine release syndrome.
Stephan A. Grupp mostly deals with Internal medicine, Chimeric antigen receptor, Oncology, Cancer research and CD19. His study brings together the fields of Gastroenterology and Internal medicine. His Chimeric antigen receptor research incorporates themes from Leukemia and Cell therapy.
His Oncology research includes themes of Hematopoietic stem cell transplantation, Disease, Clinical trial, B cell and Acute lymphocytic leukemia. His Immunotherapy research incorporates themes from Neoplasm genetics and Antigen. His T cell study results in a more complete grasp of Immunology.
Stephan A. Grupp focuses on Chimeric antigen receptor, Internal medicine, Antigen, Immunotherapy and Cell therapy. The various areas that Stephan A. Grupp examines in his Chimeric antigen receptor study include Cancer research and Disease. The study of Internal medicine is intertwined with the study of Oncology in a number of ways.
Adoptive cell transfer, Tumor microenvironment and Cytokine is closely connected to Progressive disease in his research, which is encompassed under the umbrella topic of Antigen. His research on Immunotherapy often connects related topics like T cell. His research integrates issues of Gastroenterology, Tocilizumab and Refractory in his study of Cytokine release syndrome.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude;Noelle Frey;Pamela A. Shaw;Richard Aplenc.
The New England Journal of Medicine (2014)
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A. Grupp;Michael Kalos;David Barrett;Richard Aplenc.
The New England Journal of Medicine (2013)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude;Theodore W Laetsch;J. Buechner;S. Rives.
The New England Journal of Medicine (2018)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos;Bruce L. Levine;David L. Porter;Sharyn Katz.
Science Translational Medicine (2011)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee;Rebecca Gardner;David L. Porter;Chrystal U. Louis.
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu;Andrew L. Gilman;M. Fevzi Ozkaynak;Wendy B. London.
The New England Journal of Medicine (2010)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter;Wei-Ting Hwang;Noelle V. Frey;Simon F. Lacey.
Science Translational Medicine (2015)
Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species
M. A. Goodell;M. Rosenzweig;Hyung Kim;D. F. Marks.
Nature Medicine (1997)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee;Bianca D. Santomasso;Frederick L. Locke;Armin Ghobadi.
Biology of Blood and Marrow Transplantation (2019)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone;Jonathan D. Fish;Jonathan D. Fish;Carmine Carpenito;Richard G. Carroll.
Molecular Therapy (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: